explore -WSS

explore

author：Wikipedia 2025-09-30 16:25:11 - browse：18472

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Are embryos people? Reproductive medicine's future depends on the answer

Is there really a nursing shortage in the U.S.?

Virtual repurposing can help discover new uses for existing drugs

hotspot

explore

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How AI can help patients find reliable information about doctors

Medicare details structure of new drug price negotiation program

'Vaccine

Duchenne breakthrough therapy leaves behind pioneering families

STAT Readout Newsletter: Biotech news today

Affirmative action in medical school literally saved lives

Why a market frenzy over new weight loss drugs defies logic

Heart attack and stroke risk calculators need revising

Smaller biotechs seek to piggyback on weight loss drug boom

hotspot

Children’s Hospital revives plan for pedestrian bridge

NEJM study measures Covid brain fog, impact on IQ

UnitedHealth, Optum discontinue NaviHealth name

STAT Readout Newsletter: Biotech news today

FDA clears Verve to begin U.S. study of gene

Redefining sustainability for the pharmaceutical industry

focus

focus

hotspot

Wikipedia